![Sara Isbell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Sara Isbell first degree
Entity | Entity type | Industry | |
---|---|---|---|
Mercaptor Discoveries, Inc.
![]() Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016.
3
| Private Company | Pharmaceuticals: Major | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sara Isbell via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
San Francisco State University | College/University | Undergraduate Degree | |
BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Comptroller/Controller/Auditor | |
RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director of Finance/CFO | |
SPATIALIGHT, INC. | Electronics/Appliances | Comptroller/Controller/Auditor | |
Glyko, Inc.
![]() Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Medical Specialties | Comptroller/Controller/Auditor | |
MONOPAR THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
THIOGENESIS THERAPEUTICS, CORP. | Financial Conglomerates | Director/Board Member |
Statistics
International
United States | 10 |
Canada | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 2 |
Technology Services | 2 |
Consumer Durables | 2 |
Finance | 2 |
Operational
Comptroller/Controller/Auditor | 6 |
Treasurer | 6 |
Director of Finance/CFO | 5 |
Corporate Secretary | 4 |
Director/Board Member | 3 |
Most connected contacts
Insiders | |
---|---|
Kim Tsuchimoto | 11 |
Todd Zankel | 1 |
Sheana Nieh | 1 |
- Stock Market
- Insiders
- Sara Isbell
- Company connections